(Total Views: 530)
Posted On: 01/03/2020 9:00:16 PM
Post# of 154009
Re: the lawman #14233
Pharmacyclics got a offer from their partner Johnson & Johnson, yet AbbVie beats that offer significantly, and paid $21 billion only for Pharmacyclics rights.
I personally don't think any offers will be less than $15B to $20B, and by then with the good data, which makes the offer possible, we should already be a couple of times of today price. More than $20/share is easily doable, just in 2 years with not so bad data, in most indications.
When $20 is there, with so many indications, AbbVie can beat it by $5 or more. They have done it before to get what they want.
https://en.wikipedia.org/wiki/Pharmacyclics
I personally don't think any offers will be less than $15B to $20B, and by then with the good data, which makes the offer possible, we should already be a couple of times of today price. More than $20/share is easily doable, just in 2 years with not so bad data, in most indications.
When $20 is there, with so many indications, AbbVie can beat it by $5 or more. They have done it before to get what they want.
https://en.wikipedia.org/wiki/Pharmacyclics
Quote:
In March 2015, Chicago-based biopharmaceutical firm AbbVie announced it would acquire Pharmacyclics, as well as its lead anti-cancer compound ibrutinib (Imbruvica) for $21 billion.
(0)
(0)
